How antimicrobial resistance is risking blood cancer treatment
Antimicrobial resistance threatens blood cancer care, raising infection risks, undermining trials and endangering the future of oncology innovation.
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA Connected Intelligence powers its portfolio of solutions to deliver actionable insights and accelerate innovations. With 88,000 employees, IQVIA conducts operations in 100 countries in Africa, Asia, Europe, the Middle East, Latin America and North America. IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health globally. The company has 10,000 clients worldwide and works with global health institutions, donors, local ministries and other healthcare stakeholders to improve public health.
Antimicrobial resistance threatens blood cancer care, raising infection risks, undermining trials and endangering the future of oncology innovation.
Antimicrobial resistance is known as a quiet pandemic but more data, investment, policy incentives and a holistic approach via One Health could defeat it.